Suppr超能文献

造影剂反应。

Contrast media reactions.

作者信息

Greenberger P A

出版信息

J Allergy Clin Immunol. 1984 Oct;74(4 Pt 2):600-5. doi: 10.1016/0091-6749(84)90113-1.

Abstract

Contrast media reactions may be classified as anaphylactoid, vasomotor, severe or life threatening, and fatal. Anaphylactoid reactions mimic immunoglobulin E-mediated hypersensitivity in that signs may consist of urticaria, angioedema, wheezing, dyspnea, hypotension, or shock. These reactions occur in 2% to 8% of all contrast media infusions. Vasomotor reactions occur in 5% to 8% of patients and consist of nausea, vomiting, flushing, and warmth. Severe reactions during which there is a concern for life occur about once per 1000 procedures. Fatalities have occurred in from 1:3000 procedures for intravenous cholangiography to between 1:10,000 to 1:100,000 procedures for intravenous urography. The pathogenesis of contrast media reactions is unknown, and various mechanisms may be associated with different clinical features. Radiocontrast media infusions can cause rises in plasma histamine and complement activation by either classic or alternate pathways or nonsequentially, yet adverse reactions may or may not occur. Abnormalities in the complement system or an increased conversion of prekallikrein to kallikrein has been demonstrated in some patients who have had anaphylactoid reactions. It is unknown if these mechanisms can explain the pathogenesis of anaphylactoid contrast media reactions. When patients who have had definite anaphylactoid reactions require a repeat procedure, the incidence of reactions ranges from 35% to 60% for intravascular infusion. Pretreatment with prednisone and diphenhydramine has been demonstrated to reduce this reaction rate to 9% in 465 procedures. Prednisone-diphenhydramine and ephedrine have further reduced the reaction rate to 3.1% in 192 procedures. These results are statistically significant (X2 = 5.4996, p = 0.019). Emergency equipment should be available should a severe reaction occur.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

造影剂反应可分为类过敏反应、血管舒缩反应、严重或危及生命的反应以及致命反应。类过敏反应类似于免疫球蛋白E介导的超敏反应,其症状可能包括荨麻疹、血管性水肿、喘息、呼吸困难、低血压或休克。这些反应在所有造影剂输注中发生率为2%至8%。血管舒缩反应发生在5%至8%的患者中,表现为恶心、呕吐、潮红和发热。每1000例检查中约有1例会出现危及生命的严重反应。静脉胆管造影的死亡率为1:3000,静脉肾盂造影的死亡率为1:10000至1:100000。造影剂反应的发病机制尚不清楚,各种机制可能与不同的临床特征相关。放射性造影剂输注可导致血浆组胺升高以及补体通过经典途径或替代途径激活,或非顺序激活,但不良反应可能发生也可能不发生。在一些发生类过敏反应的患者中已证实补体系统异常或激肽释放酶原向激肽释放酶的转化增加。尚不清楚这些机制是否能解释类过敏造影剂反应的发病机制。当曾发生明确类过敏反应的患者需要再次检查时,血管内输注的反应发生率为35%至60%。在465例检查中,已证明用泼尼松和苯海拉明预处理可将该反应率降至9%。在192例检查中,泼尼松-苯海拉明和麻黄碱进一步将反应率降至3.1%。这些结果具有统计学意义(X2 = 5.4996,p = 0.019)。若发生严重反应,应备有急救设备。(摘要截选至250字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验